手术切除的N2期非小细胞肺癌预后影响因素分析

李 壮志1, 李 忠诚2
1、青海大学研究生院
2、青海大学附属医院胸外科

摘要


非小细胞肺癌是肺癌的主要类型,占所有肺癌病例的80%以上。N2期NSCLC指肿瘤已侵犯纵隔淋巴结,
但未累及对侧纵隔、肺门或同侧斜角肌淋巴结的肺癌。手术切除是N2期非小细胞肺癌的主要治疗手段之一,但患者
的预后差异显著。因此,分析影响N2期非小细胞肺癌手术切除患者预后的因素,对于提高治疗效果、延长患者生存
期具有重要意义。

关键词


手术切除;N2期非小细胞肺癌;影响因素

全文:

PDF


参考


[1]Fu Fangqiu, Sun Wenrui, Bai Jinsong, Deng

Chaoqiang, Zheng Difang, Li Yuan, Zhang Yang, Chen

Haiquan. Long-Term Outcomes of Selected Patients with

IIIA-N2Non-small Cell Lung Cancer Receiving Upfront

Surgical Resection[J]. Annals of surgical oncology, 2023,

30(13): 8261-8270.

[2]Lee Jang Hyuck, Park JiEun, Hong MiJeong, Choi

JinEun, Kang HyoGyoung, Do SookKyung, Lee Sunwoong,

Jeong JiYun, Shin KyungMin, Do YoungWoo, Lee EungBae,

Lee WonKee, Oh InJae, Kim YoungChul, Choi SunHa, Lee

YongHoon, Seo Hyewon, Lee Jaehee, Cha SeungIck, Kim

ChangHo, Yoo SeungSoo, Lee ShinYup, Park JaeYong. Gen

eticvariantsinkeynecroptosisregulatorspredictprognosisofnonsmallcelllungcanceraftersurgicalresection.[J]. Thoraciccancer,

2023, 14(26): 2678-2686.

[3]Müller Christin, Taber Samantha, Pfannschmidt

Joachim, Griff Sergej. ExtracapsularextensionofpN2ly

mphnodemetastasesisnotprognosticallysignificantinsur

gicallyresectedpatientswithnon-smallcelllungcancer[J].

InnovativeSurgicalSciences, 2023, 8(1):9-16.

[4]Azzoli Christopher, Huynh Lynn, Yi Denise, Duh

Mei S, Cai Beilei. Authors' Responseto "Letter to the

Editor" Submittedby S.Wangand W.Liu(re:"Retrospective

Study to Examine Prognostic Valueof C-Reactive Proteinin

Patients With Surgically Resectable Non-Small-Cell Lung

Cancer"[J]. Clinicallungcancer, 2023, 24(6): e197-e197.

[5]Wang Sujuan, Liu Wenqing. Commentson"Retrospective Study to Examine Prognostic Valueof

C-Reactive Proteinin Patients With Surgically Resectable

Non-Small Cell Lung Cancer"[J]. Clinicallungcancer, 2023,

24(6): e195-e196.

[6]Liu Wenliang, Ren Siying, Zeng Chao, Hu

Yan. Prognosticvalueofperineuralinvasioninresectednonsmallcelllungcancer:Ameta-analysis[J]. Heliyon, 2023, 9(4):

e15266-e15266.

[7]Mazzella Antonio, Maiolino Elena, Maisonneuve

Patrick, Loi Mauro, Alifano Marco. Systemic Inflammationand

Lung Cancer: Is Ita Real Paradigm? Prognostic

ValueofInflammatory Indexesin Patientswith Resected NonSmall-CellLung Cancer[J]. Cancers, 2023, 15(6): 1854-1854.

[8]Kang Seung Wan, Jeong Won Gi, Lee Jong Eun,

Oh In Jae, Song Sang Yun, Lee Byung Chan, Kim Yun

Hyeon. Prognosticsignificanceoflocationindexinresected T1-

sizedearly-stagenon-smallcelllungcancer[J]. Acta Radiologica,

2023, 64(3): 1028-1037.

[9]Azzoli Christopher, Huynh Lynn, Yi Denise,

Duh Mei S, Cai Beilei. Retrospective Studyto Examine

Prognostic Valueof C-Reactive Proteinin Patients With

Surgically Resectable Non-Small-CellLung Cancer.[J].

Clinicallungcancer, 2023, 24(4): 329-338.

[10]Zeng Yuan, Liu Jun, Wan Minghui, Li Qiwen, Liu

Hui, Cui Fei, Hao Zhexue, Wang Wei, Jiang Long, Liang

Wenhua, He Jianxing. Theassociationofpostoperativeradiot

herapywithsurvivalinresectedN2non-smallcelllungcancer[J].

Journalofthoracicdisease, 2023, 15(1): 42-53.

[11]T.Miyoshi, A.Hamada, J.Soh, A.Hata, K.Nakamatsu,

M.Shimokawa, Y.Yatabe, J.Suzuki, M.Tsuboi, H.Horinouchi,

I.Yoshino, T.Masayuki, S.Toyooka, M.Okada, T.Go,

M.Yamashita, Y.Nishimura, N.Yamamoto, K.Nakagawa,

T.Mitsudomi. 124PPhaseIIstudyofneoadjuvantconcurrentche

mo-immuno-radiationtherapyfollowedbysurgeryandadjuvan

timmunotherapyforresectablestageIIIA-BN2non-smallcelllun

gcancer:SQUATtrial(WJOG12119L)[J]. Immuno-Oncology

and Technology, 2022, 16(S1):100236-.

[12]余军林,崔抗,李向荣.放化疗对手术切除的

Ⅰb期非小细胞肺癌患者预后的影响[J].肿瘤基础与临

床,2023,36(06):465-471.

[13]牛新燕,方香香,索仲.手术切除的N2期非小

细胞肺癌预后影响因素分析[J].实用癌症杂志,2023,38

(08):1270-1272+1316.

[14]吴茂芳,石汶,肖寿勇,蔡静静,刘曾平,方

红.ⅢA/N2期非小细胞肺癌患者术后放疗的倾向评分匹

配分析[J].大理大学学报,2023,8(08):64-70.

[15]李润锋.基于SEER数据库的ⅢA-N2期非小细

胞肺癌患者预后分析及预后模型构建[D].南方医科大学,

2023.

[16]赵豪南.可切除的ⅢAN2期非小细胞肺癌术后复

发独立因素分析及不同辅助治疗预后差异研究[D].广州

医科大学,2023.


Refbacks

  • 当前没有refback。